These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22483068)

  • 21. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
    Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
    Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine: in myelodysplastic syndromes.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(13):1781-9; discussion 1790-1. PubMed ID: 16114977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azacitidine-induced Sweet syndrome: Two unusual clinical presentations.
    Tiwari SM; Caccetta T; Kumarasinghe SP; Harvey N
    Australas J Dermatol; 2018 Aug; 59(3):e224-e225. PubMed ID: 29044459
    [No Abstract]   [Full Text] [Related]  

  • 25. Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan.
    Hayashi M; Takayasu H; Tada M; Yamazaki Y; Tateno H; Tazawa S; Wakabayashi A; Iwasaki T; Tsuchiya Y; Yamashita J; Takeda N; Tomita S; Mori H; Kokubu F
    Intern Med; 2012; 51(17):2411-5. PubMed ID: 22975559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment.
    Feldmann G; Brossart P; von Lilienfeld-Toal M
    Ann Hematol; 2013 Nov; 92(11):1577-9. PubMed ID: 23584506
    [No Abstract]   [Full Text] [Related]  

  • 27. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
    Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
    Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of CD41-positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine.
    Ogata K; Sei K; Kawahara N; Yamamoto Y
    Br J Haematol; 2020 May; 189(4):e144-e147. PubMed ID: 32130725
    [No Abstract]   [Full Text] [Related]  

  • 30. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 31. Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine.
    Lai SW; Huang TC; Ye RH; Wu YY
    Eur J Haematol; 2015 Mar; 94(3):273-6. PubMed ID: 24797511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decitabine in myelodysplastic syndromes: viewpoints.
    Garcia-Manero G; Saba HI
    Drugs; 2006; 66(7):959-60. PubMed ID: 16740015
    [No Abstract]   [Full Text] [Related]  

  • 33. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
    Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
    [No Abstract]   [Full Text] [Related]  

  • 34. Myelodysplastic syndromes (MDS).
    Klimek V
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
    [No Abstract]   [Full Text] [Related]  

  • 35. 5-Azacytidine for the treatment of myelodysplastic syndromes.
    Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
    Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry.
    Grinblatt DL; Sekeres MA; Komrokji RS; Swern AS; Sullivan KA; Narang M
    Leuk Lymphoma; 2015 Apr; 56(4):887-95. PubMed ID: 24956145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.
    Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G
    Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826
    [No Abstract]   [Full Text] [Related]  

  • 38. Neutrophilic eccrine hidradenitis associated with decitabine.
    Ng ES; Aw DC; Tan KB; Poon ML; Yap ES; Liu TC; Tan LK; Chng WJ; Koh LP
    Leuk Res; 2010 May; 34(5):e130-2. PubMed ID: 20022375
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes.
    Uchida T; Ogawa Y; Kobayashi Y; Ishikawa T; Ohashi H; Hata T; Usui N; Taniwaki M; Ohnishi K; Akiyama H; Ozawa K; Ohyashiki K; Okamoto S; Tomita A; Nakao S; Tobinai K; Ogura M; Ando K; Hotta T
    Cancer Sci; 2011 Sep; 102(9):1680-6. PubMed ID: 21624006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.